Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

"First ""All-in-one"" and Adjustable Supraglottic Airway Device for a Safely Clinical Airway Management"

Project description

A breath of fresh air whenever and wherever it is needed

A steady flow of oxygen is paramount to the outcome of any treatment. Mask ventilation is common and, in the case of airway obstruction, tracheal intubation is an invasive alternative. Supraglottic airway devices (SADs) that can be inserted into the pharynx through the mouth are somewhere in between and have become a mainstay of emergency management. The market for improved designs allowing more widespread use is growing. The Swiss SME Singularity is addressing this demand with a universal tool that covers all the functions offered by the other SADs but is safer and less expensive. The EU-funded Safe SAD project is supporting technology optimisation and providing a roadmap for commercialisation.

Objective

Singularity AG is a medical device company created in 2012, in Zürich. The inspiration driving the company was to design an advanced unique 2nd generation Supraglottic Airway Device (SAD). The original design of “Singularity SAD” offers an innovative, versatile, cheaper and safer alternative compared to the current static SADs. It avoids unnecessary risks and complications associated to insertion, maintenance and manipulation of patients under anesthesia and can be used in most situations requiring airway management. Two different series of SAD have been developed, the SAD Air and the SAD Compact, different parts of which have been patented for diverse uses and licensed in several countries. All pieces of these devices have been specifically designed to allow for the full mechanization of production, which ensures a competitive price using cost-effective manufacturing technologies. The shareholders of Singularity AG are Mr. Werner Dubach and Mr. Fabio Hausammann, who have an extensive experience in the production of devices and have developed Singularity in cooperation with Prof. Dr. Markus Weiss, who completed the team with his medical expertise. The Singularity project has received the support of relevant companies and institutions for its development, which has motivated the current TRL 6. The “all-in-one functional design” of Singularity SADs makes it a universal tool that covers all the functions offered by the other SADs. The demand for this type of device is estimated at more than 150 million units per year. The wide range of applications and extended use under anesthesia ensure the massive and continuous use of SADs. The functionality of Singularity has been successfully tested using the SAD Air prototype in the prestigious Schulthess Klinik (Zürich), which has an experienced anesthesiology team. The unit at size 4 has been fully produced for validation in clinical tests, showing excellent results in an initial study with 10 patients.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

SINGULARITY AG
Net EU contribution
€ 50 000,00
Address
HUBRAINSTRASSE 4
8124 MAUR
Switzerland
SME
Yes
Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00